- Home
- SOND vs CMMB Comparison
SOND vs CMMB Comparison
Compare SOND & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOND
- CMMB
- Stock Information
- Founded
- SOND 2014
- CMMB 2004
- Country
- SOND United States
- CMMB Israel
- Employees
- SOND N/A
- CMMB N/A
- Industry
- SOND Hotels/Resorts
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- SOND Consumer Discretionary
- CMMB Health Care
- Exchange
- SOND Nasdaq
- CMMB Nasdaq
- Market Cap
- SOND 23.2M
- CMMB 23.0M
- IPO Year
- SOND N/A
- CMMB N/A
- Fundamental
- Price
- SOND $1.77
- CMMB $1.32
- Analyst Decision
- SOND
- CMMB Strong Buy
- Analyst Count
- SOND 0
- CMMB 2
- Target Price
- SOND N/A
- CMMB $8.50
- AVG Volume (30 Days)
- SOND 36.1K
- CMMB 109.4K
- Earning Date
- SOND 06-10-2025
- CMMB 05-15-2025
- Dividend Yield
- SOND N/A
- CMMB N/A
- EPS Growth
- SOND N/A
- CMMB N/A
- EPS
- SOND N/A
- CMMB N/A
- Revenue
- SOND $624,458,000.00
- CMMB N/A
- Revenue This Year
- SOND $28.50
- CMMB N/A
- Revenue Next Year
- SOND $17.62
- CMMB N/A
- P/E Ratio
- SOND N/A
- CMMB N/A
- Revenue Growth
- SOND 8.32
- CMMB N/A
- 52 Week Low
- SOND $0.88
- CMMB $0.78
- 52 Week High
- SOND $10.50
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- SOND 29.35
- CMMB 50.69
- Support Level
- SOND $1.73
- CMMB $1.31
- Resistance Level
- SOND $2.15
- CMMB $1.44
- Average True Range (ATR)
- SOND 0.12
- CMMB 0.08
- MACD
- SOND -0.03
- CMMB 0.00
- Stochastic Oscillator
- SOND 6.20
- CMMB 54.55
About SOND Sonder Holdings Inc.
Sonder Holdings Inc is engaged in providing short and long-term accommodations to travelers in various cities across North America, Europe, and the Middle East. The Sonder units in each apartment-style building and each hotel property are selected, designed, and managed directly by the Company. The Company generates revenues by providing short-term or month-to-month accommodations to its guests. The Company also provides accommodations to travelers through boutique hotels.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.